Is KPV Approved Anywhere? What the Data Say
KPV holds no marketing authorisation in any jurisdiction and every study behind it is preclinical. What the murine colitis work shows, and why the gut.
Alpha-melanocyte-stimulating hormone is best known for what its name says: it tells melanocytes to make pigment. Less well known is that the same molecule is a potent anti-inflammatory signal, and that the two activities do not live in the same part of the sequence.
KPV is what happens when you keep the second one and discard the first.
Three amino acids
KPV is lysine-proline-valine — residues 11 to 13 of α-MSH, the C-terminal end of a 13-amino-acid hormone. Three residues is about as small as a peptide gets while still being called one.
The reason a fragment this short retains activity is that the anti-inflammatory signalling associated with α-MSH does not require the full molecule. Work on human keratinocytes published in the Journal of Investigative Dermatology examined signalling by α-MSH, the KPV fragment and ACTH side by side in the same cell system — which is how the contribution of the tripeptide gets separated from that of its parent.
A 2003 review in the Annals of the New York Academy of Sciences set out the wider picture: α-MSH and related peptides act on the immune system, dampening inflammatory signalling, and this is a distinct function from pigmentation.
Why is KPV always discussed in the context of the gut?
Most of the substantive research on KPV concerns inflammatory bowel disease, and there is a mechanistic reason for that rather than an accident of funding.
KPV is a substrate for PepT1, a di- and tripeptide transporter expressed in intestinal epithelium — and upregulated in inflamed intestinal tissue. A molecule that the inflamed gut actively imports is unusually well matched to that target.
| Study | Model | What was reported |
|---|---|---|
| Inflammatory Bowel Diseases, 2008 | Murine IBD models | Anti-inflammatory potential of the tripeptide |
| Molecular Therapy, 2017 | Murine ulcerative colitis | Orally delivered KPV in hyaluronic-acid-functionalised nanoparticles alleviated colitis |
The 2017 study is worth reading carefully, because the delivery system is doing a large share of the work. The point of the nanoparticle was to get the peptide to the inflamed tissue in the colon rather than have it absorbed or degraded on the way. The result belongs to KPV delivered that way, not to KPV in general.
Are there human trials of KPV?
None that establish anything. The gap is the same one that runs through most of this category, and it is worth stating without softening:
- No completed human trial establishes efficacy for any indication.
- No regulator has approved KPV as a medicine.
- Almost all of the work is in mice or in cell culture.
Murine colitis models are a genuine and widely used tool, and they have produced treatments that went on to work. They have also produced a long list of compounds that looked excellent in mice and did nothing in people. Preclinical promise is a reason to run a trial, not a substitute for having run one.
Anti-inflammatory activity is also not automatically a benefit. Inflammation is a defence, and suppressing it has costs as well as effects — which is precisely the sort of trade-off that human trials exist to quantify, and which has not been quantified here.
The July 2026 recommendation
On 23 July 2026 the FDA’s Pharmacy Compounding Advisory Committee recommended that KPV be added to the 503A bulk drug substances list. That is a recommendation and not a rule: it does not approve KPV, does not make it compoundable, and does not change what a pharmacy may do today. It is the first of four stages, and the remaining three carry no deadline — the full sequence is here.
It also has no bearing on the section above. A substance can be judged eligible for compounding while every line of that evidence summary stays true. Eligibility and demonstrated efficacy are separate questions, settled by different tests.
Practical notes
Handling follows the ordinary rules. KPV is supplied lyophilised, and the stability change on adding water is the one described in peptide storage; the arithmetic of getting from a vial to a measured volume is in reconstitution and concentration, or run it through the reconstitution calculator.
Frequency is where the preclinical status bites hardest. KPV has no published human half-life — see the half-life table — and the best-studied route in the literature is targeted delivery to the colon rather than systemic exposure, so even the animal work does not transfer cleanly to an interval.
For a compound whose evidence is entirely preclinical, the value of a record is mostly negative information: it tells you what you actually did, so that anything you notice can be checked against the timeline rather than against your recollection of it. That is a low bar, and it is still higher than most people clear.
Frequently asked questions
What is KPV?
A tripeptide of lysine, proline and valine — the last three amino acids (residues 11–13) of alpha-melanocyte-stimulating hormone. It retains anti-inflammatory activity associated with the parent hormone while being far smaller.
Does KPV cause skin darkening like α-MSH?
The pigmentation effect of alpha-MSH depends on a different region of the molecule binding melanocortin receptors on melanocytes. KPV is the C-terminal tripeptide and is studied for the anti-inflammatory activity rather than the pigmentary one.
Are there human trials of KPV?
No completed trial has established efficacy or safety in humans. The published work is preclinical — cell studies and murine models of inflammatory bowel disease — and KPV holds no marketing authorisation anywhere.
Why is KPV so often discussed in the context of the gut?
Because that is where the strongest preclinical work is. KPV is a substrate for PepT1, a peptide transporter expressed in intestinal epithelium, which gives it a route into exactly the tissue affected in colitis. Studies in murine models of inflammatory bowel disease, including one using nanoparticle delivery, are the core of its evidence base.
Sources
- Inflammatory Bowel Diseases (2008) — Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease
- Molecular Therapy (2017) — Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis
- Journal of Investigative Dermatology (2004) — alpha-Melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells
- Annals of the New York Academy of Sciences (2003) — New insights into the functions of alpha-MSH and related peptides in the immune system